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In the current issue of Annals of Oncology, Lote and colleagues shed light on the timelines of 
metastatic dissemination in a colorectal cancer patient [1]. We have long known that the 
process leading from a primary neoplasm to the formation of metastases involves years 
(often decades) [2-4].  However the precise timelines of each step have been difficult to 
estimate with accuracy.  Lote and coworkers exploited a clever approach involving clinical 
annotation of metastasis seeding coupled to mathematic calculations to reconstruct the 
chronological evolution of a colorectal cancer.  
 
The concept that cancer cell populations clonally volve was proposed in 1976 by Peter 
Carey Nowell [5]. In his model, the tumor is the result of changes occurring in a normal cell, 
which displays a selective growth advantage over the general population. Over time 
neoplastic cells acquire additional genetic differences while maintaining similarities with their 
ancestors.  
 
While the idea that tumor evolves in time is not novel, only the availability of DNA Next 
Generation Sequencing (NGS) technologies and the development of dedicated bioinformatic 
tools allowed precise assessment of cancer evolution parameters [6, 7]. Several evidences 
indicate that tumors develop through progressive clonal sweeps associated with acquisition 
of somatic mutations [2, 8].  In analogy with the structure of trees, ‘trunk’ mutations represent 
the complement of genetic alterations shared by all malignant cells within a tumor. Molecular 
alterations that occur early are present in every sub-clone, indicating that there must have 
been a single ancestral cell. All mutations that occur after the most recent appearance of a 
common ancestor are instead sub-clonal (branched mutations). Most of the molecular 
alterations acquired during evolution do not immediately affect tumor fitness (passengers 
Page 1 of 7 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
mutations), while a subset of the variations (driver mutations) provides a selective advantage 
[9]. Building on these premises mathematical models and bioinformatic tools were developed 
to track clonal evolution and reconstruct phylogenetic trees of cancers dissemination [10]. 
Importantly, virtually all models infer the structures of phylogenetic tree by assuming that 
each sub-clone maintains all the alterations of its ancestors [6, 7].  
 
The study by Lote and colleagues adds importantly to previous work, such as the analysis of 
Andor and colleagues which deduced the clonal architecture of 12 different tumor types [11] 
using ad hoc bioinformatics tools such as PyClone and Expands [6, 7]. By focusing on the 
presence of founder (ancestor) clones across each tumor, these studies showed that the 
clonal architecture in different tumor types is highly heterogeneous and demonstrated 
univocal temporal evolution in individual tumors.  In another landmark study, Murtaza and 
colleagues [12] used molecular profiles from tumor biopsies and circulating tumor DNA [13] 
to define the clonal architecture of metastatic breast cancer. Noteworthy results were also 
obtained examining clonal pattern at single cell resolution.  In another investigation, Navin 
and colleagues [14] analyzed hundreds of cells in a primary tumor, thus revealing diverse 
sub-clonal populations and showing that tumor progression was sustained by punctuated 
clonal expansions. In colorectal cancer, Sottoriva and colleagues [15] proposed a “Big Bang” 
model for tumor growth. This model assumes that cancer grows as a single expansion, 
which leads over time to clonal sweeps that are not subjected to stringent selection.  
 
Overall previous studies indicate that genomic data and mathematical models can be 
successfully coupled to infer phylogenetic trees, while the precise timeline of evolution of 
individual metastatic lesions is difficult to calculate.  While genomic profiles and 
mathematical calculations can provide estimations for the timing of metastasis 
disseminations, clinical data remain essential to conform the predictions [16, 17].  
 
How can we know exactly when an individual metastatic deposit was initiated?  
 
One way is to exploit molecular clock methods to infer evolutionary timescales using genetic 
data [16]. To achieve this, Lote and colleagues cleverly exploited a rather infrequent clinical 
event: the formation of iatrogenic metastasis, which occasionally result from needle tract 
seeding [18].  They studied a 68 years old male that underwent a CT-guided lung biopsy to 
establish a diagnosis of metastatic colorectal carcinoma. Approximately two years later, 
FDG-PET-CT examination showed an unresectable left posterior chest wall mass at the site 
of the aforementioned lung biopsy. The day of the biopsy procedure therefore represents the 
time when the chest wall metastasis was originated. This information served as an in vivo 
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stopwatch to calibrate timing of evolution for the overall disease (Figure 1). To describe the 
methods they used, Lote and colleagues refer to ‘carbon dating’, a technique developed by 
geologists and evolutionary biologists, based on the decay of carbon-14 isotope that allows 
establishing the age of organic materials [19]. Translated in the clinical setting, a fixed 
tracking event (the iatrogenic metastasis formation) is used instead of carbon decay to 
calibrate the model and infer timing of the overall phylogenetic tree.  
 
Combining this approach and bioinformatic methodologies [20] the authors initially estimated 
the chronology of formation of the primary tumor. This revealed that this particular colorectal 
cancer required over a decade to fully develop, a finding in line with previous studies that 
have shown similar or longer timelines for mCRC development [4]. The molecular clock 
information was further used to accurately determine timing of metastatic deposits in the 
lung, thyroid and urinary tract. This revealed that the colorectal cancer first metastasized to 
thyroid and lung; followed by the lung metastasis which eventually led to the chest wall 
lesion. Finally the disease metastasized to the left ureter. Thanks to the stopwatch approach 
the authors calculated that the primary colon cancer emerged between five and eight years 
prior to the clinical diagnosis and that the primary tumor metastasized to the lung and the 
thyroid within a year from its onset.  As the authors acknowledge, some of the clinical 
features of this patient are rather peculiar and this cannot be considered a textbook case of 
colorectal cancer, accordingly it is unclear how broadly applicable are the findings.  
 
Overall, the report by Lote and colleagues provides compelling evidence of how cross-
fertilization among different disciplines (mathematics, informatics, evolutionary biology and 
oncology) can address challenging questions such as tracking cancer evolution in time and 
space. Considering the extensive analogies between evolution of species under natural 
selection and tumor progression over time, it is likely that concepts and methods derived 
from evolutionary studies will further help our understanding of how and when cancer arise 
and metastasize. 
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Figure 1  
Spatial and temporal evolution of a colorectal cancer (A) Clinical time-line. In November 
2008 a primary colon tumor was excised from a 68 year old Caucasian male. Three years 
later radiological imaging revealed a lung lesion and a new nodule in the left lobe of the 
thyroid. At the same time a CT-guided biopsy confirmed that the primary tumor had 
metastasized to the lung. In September 2013, a PET-CT demonstrated a chest wall mass 
caused by malignant cells seeding from the needle biopsy. In August 2014 a new urinary 
tract metastasis was diagnosed. (B) Phylogenetic time-line. The graphical representation 
(phylogenetic tree) shows chronological evolution of the disease. The lung biopsy was used 
as a tracking event to calibrate the molecular clock model. 
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